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Association studyActivating transcription factor 1 (ATF1) may be involved in essential hypertension (EH) by induction
of NADPH oxidase 1 (NOX1) and radical oxygen species (ROSs) production. Abnormal expression of
ATF1 was found in EH in previous microarray analysis. Here we tested whether a single nucleotide
polymorphism (SNP) located in the 30-untranslated region (30UTR) of ATF1 was associated with EH
susceptibility by affecting microRNA (miRNA) binding. In silico analysis indicated that rs11169571
(T > C) was a candidate SNP to modulate miRNA: ATF1 mRNA complex, with the greatest changed
energy for hsa-miR-1283, and the luciferase reporter analysis showed that miR-1283 inhibited the
activity of the reporter vector carrying –T allele, but not the –C allele. In addition, inhibition of
miR-1283 in HA-VSMCs enhanced the expression of ATF1 mRNA as well as the ROS levels. Further
case-control study showed that rs11169571 was signiﬁcantly associated with increased risk of EH.
Finally, we observed an increased ATF1 protein level in peripheral blood of EH patients with CC car-
riers compared to TT carriers of rs11169571, with an intermediate ATF1 level in TC carriers. These
results suggested that rs11169571 of ATF1 gene may be associated with EH, and the SNP-modiﬁed
posttranscriptional gene regulation bymiRNAs could be a potentially pathogeneticmechanism of EH.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Essential hypertension (EH) has long been a major health bur-
den due to its association with an increased risk for certain vascu-
lar disorders, such as myocardial infarction and stroke. Increasing
evidence shows genetic inﬂuences on the high prevalence
of EH. Such evidence includes familial studies, twin studies,
speciﬁc genetic factors, and genome-wide association studies, allindicating that EH could be related with genetic factors in addi-
tional to environmental ones [1–3]. Consequently, we have con-
ducted a comparative study of the differential gene expression
between EH patients and normotensives by microarray analysis
[4] and identiﬁed 31 up-regulated genes and 18 down-regulated
genes in expression, among which, ATF1 was signiﬁcantly
up-regulated with 3.24-fold change.
Activating transcription factor 1 (ATF1), a member of the
cAMP-response-element-binding protein (CREB)/ATF family, may
be involved in hypertension through induction of NOX1, a catalytic
subunit of NAPDH oxidase. Quite a few models of hypertension
have revealed that elevation in radical oxygen species (ROSs) was
related with hypertension, including spontaneously hypertensive
rats [5], DOCA-salt administration [6], and animals subjected to
infusion of angiotensin II [7] or norepinephrine [8]. Further
research indicated that the NADPH oxidase (NOX) family was the
main source of ROS production in vascular smooth muscle cells
(VSMCs) exposure to pathologic stimulus [9]. Among the NOX fam-
ily, NOX1 may be essential in the pathogenesis of arteriosclerosis
and vascular injury, since it mediated the migration, proliferation
and hypertrophy of VSMCs [10]. Masato et al. [11] has reported
for the ﬁrst time that ATF1 may play a pivotal role in the
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transactivation of the EGF receptor and a PI3 kinase–ATF1 pathway
was found involved in the up-regulation of NOX1 by induction of
PGF2a [12]. In addition, ATF1-silencing using RNA interference
attenuated aldosterone-induced O2 production and inhibited
hypertrophy in VSMCs [13]. These reports suggested that ATF1
played important roles in hypertension, and quantitative change
in ATF1 expression would result in increased risk for EH.
Evidence has revealed that single nucleotide polymorphisms
(SNPs) in the 30 untranslated region (30UTR) could alter the genes
expression, and one critical mechanism was mediated by
microRNAs (miRNAs) [14]. MiRNAs are short (17–25 nucleotides)
non-coding RNAs that regulate gene expression at the
post-transcriptional level through binding to the 30UTR of target
mRNAs, either resulting in inhibition of mRNA translation or
induction of its degradation [15]. Evidence of SNPs in the 30UTR
affecting miRNAs0 function has been shown in cancer or cardiovas-
cular diseases [16–18]. Among BRCA2 mutation carriers,
Kontorovich et al. found that the heterozygote SNP carriers of
rs11169571 from the 30UTR of ATF1 had an 2-fold increased risk
for developing breast/ovarian cancer [19], which indicated the
potential signiﬁcance of the SNPs in the 30UTR of ATF1 with dis-
ease. However, whether SNPs in the 30UTR of ATF1 alter miRNAs’
functions and are therefore involved in EH remains undetermined.
Given this background, we hypothesized that SNPs in the 30UTR of
ATF1 gene regulated the expression of ATF1 by affecting speciﬁc
miRNA binding and altered the risk of EH. Accordingly, we con-
ducted a case-control study to select the positive SNPs in the
30UTR of ATF1 gene and further examined the potential modiﬁca-
tion of the SNP to miRNAs in EH. Recently, the use of publicly avail-
able online database MirSNP (http://cmbi.bjmu.edu.cn/mirsnp)
[20], which is a collection of human SNPs in predicted miRNA–
mRNA binding sites, makes it easier to identify the putative
miRNA-related SNPs and provide the basis for subsequent func-
tional research.
2. Materials and methods
2.1. In silico prediction of the SNP in the 30UTR of ATF1 to affect
miRNAs binding
SNPs become more important if they have a high frequency, so
the genotype frequencies of SNPs within the 30UTR region of ATF1
gene in the SNP database (dbSNP) were searched. We observed
that rs11169571 met the criterion of minor allele frequency
(MAF) > 0.05 in Asian population. We then searched in database
MirSNP for the miRNAs whose function could be modiﬁed by
rs11169571.
2.2. Subjects
Participants of Han people in Jilin area in the study aged from
25 to 69 were recruited from the medical physical examination
center in China–Japan Union Hospital of Jilin University, from 1
May 2013 to 30 April 2014. Blood pressure was measured twice
with a 5-min interval by cardiologists according to the common
protocol recommended by the European Society of Hypertension
[21]. The inclusion criteria of hypertension were as follows: the
average systolic blood pressure (SBP)P 140 mmHg and/or the
average diastolic blood pressure (DBP)P 90 mmHg and/or
self-reported current treatment for hypertension with
anti-hypertensive drugs. The control group satisﬁed both the
SBP < 140 mmHg and DBP < 90 mmHg, and have never been trea-
ted for hypertension. The exclusion criteria were as follows: (1)
secondary hypertension; (2) primary renal disease; (3) the endo-
crine disease and diabetes. The height, weight, SBP, DBP, heart rate(HR), high density lipoprotein cholesterol (HDL-c), low density
lipoprotein cholesterol (LDL-c), fasting blood glucose (FBG), triglyc-
eride (TG), total cholesterol (TC) were measured. Body mass index
(BMI) was equal to weight in kilograms divided by height in meters
squared. The smoking history and drinking history was inter-
viewed, and participants who smokedP 100 cigarettes or
drankP 12 times a year were deﬁned as smokers or drinkers
[22,23]. Eventually 378 cases of EH, with age and sex-matched
423 cases of normal blood pressure control, were recruited in the
present study. This study complies with the 1975 Declaration of
Helsinki, the institution ethics committee of China–Japan Union
Hospital of Jilin University, China. Written informed consent was
obtained from each participant.
2.3. Genotyping
Genomic DNA was prepared from whole blood samples using
an AxyPrep genomic DNA extraction kit (Axygen Scientiﬁc, CA,
USA). The SNP rs11169571 was identiﬁed by PCR-sequencing with
ﬁve DNA pools of twenty samples in each pool, and the SNP was
genotyped through PCR–RFLP (polymerase chain reaction–restric-
tion fragment length polymorphism) with the restriction enzyme
Hind III, which had the ability to digest the wild DNA sequence,
but not the mutant one. Then the genotype was identiﬁed by 3%
agarose gel electrophoresis for the products of digestion, with
one band indicated CC, two bands indicated TT and three bands
indicated TC genotype. In order to increase the accuracy, two indi-
viduals separately made the statistics of enzymic electrophoresis
bands. For the inconsistent results, we would reconduct the geno-
typing until no inconsistency. The PCR product of each genotype
sample (TT, TC and CC) was randomly sequenced to verify the
accuracy. The sequencing reaction was performed by Sangon
Biotech (Shanghai). The primer using for PCR ampliﬁcation and
sequencing was as follows: forward, 50-CGCACGATATCTAGTGACA
GAGG-30; reverse, 50-TGCAAACCTGTAGGGTAAATGG-30.
2.4. Comparison of the genotypes with the clinical characteristics
To compare the clinical parameters among different genotypes
of rs11169571, we chose the EH patients who never treated with
anti-hypertensive drugs. As a result, we obtained 74 cases of TT
carriers, 165 cases of TC carriers and 40 cases of CC carriers,
respectively.
2.5. ELISA detection
From the EH population, we selected 90 patients for ATF1
expression detection according to the genotypes of TT, TC or CC
of rs11169571, the sample of each group being thirty, with age
and sex among these 3 groups matched. In addition, another 50
controls were also selected for the detection of ATF1 to validate
the differentially expression of ATF1 between the EH and control
group in our previous microarray result. The ATF1 expression level
was determined by enzyme-linked immunosorbent assay (ELISA)
with a human ATF1 ELISA test kit (IBL, Germany) according to
the manufacturer’s instructions.
2.6. Luciferase reporter assay
A reporter construct derived from the pmiR-RB-Report vector
(RiboBio Co., Ltd., China) containing the 30UTR region of ATF1
was generated. Human DNA with homologous genotypes of the
30UTR polymorphism rs11169571 (either CC or TT) was used as
PCR template to generate allele-speciﬁc amplicons, and two
704 bp fragments of the ATF1 30UTR were ampliﬁed from
genomic DNA using the following primer sequences: forward,
Table 1
The miRNAs being affected by rs11169571 of ATF1 gene.
Gene miRNA mirSVR Effect Allele Score Energy
ATF1 hsa-miR-1283 0.552 Create C
T 145.00 13.58
ATF1 hsa-miR-520d-5p 0.333 Create C
T 140.00 12.07
ATF1 hsa-miR-524-5p 0.331 Create C
T 140.00 12.19
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Not I loci underlined in the 50 end; reverse,
50-CCGCTCGAGTAAAGCACAGCAGAATAAGTAATGG-30 with enzyme
Xho I loci underlined in the 50 end. The ampliﬁed product was
cloned to the pMDTM18-T Simple Vector (Takara, China). Then
the clone was double-digested with Not I and Xho I restriction
enzymes (NEB, USA) and subcloned into the similarly digested
pmiR-RB-Report vector. The constructs were validated by sequenc-
ing and did not contain any other sequence variations.
The 293T cell line was cultured in DMEM with 10% fetal bovine
serum (Invitrogen, USA) and was passaged into 48-well culture
plates (Corning, Inc., Corning, NY, USA) at 4  104 cells per well.
Twelve hours after plating, hsa-miR-1283 or the scrambled
miR-control (all at 50 nM, RiboBio Co., Ltd., China) was cotrans-
fected with 80 ng of wild-type (T) or mutant-type (C) ATF1 reporter
construct or empty vector using lipofectamine 2000 (Invitrogen,
USA). Five replicates were performed for each treatment,
forty-eight hours after transfection, the cells were harvested. We
analyzed using the Dual-Luciferase Reporter Assay System
(Promega, USA), with hRluc as the reporter gene and hluc+ as the
internal reference, and measured in a FLUOstar Optima microplate
reader (BMG Labtech, Australia).
2.7. Hsa-miR-1283 and ATF1 expression detection
Human aorta vascular smooth muscle cells (HA-VSMCs) was
cultured in high sugar DMEM with 10% fetal bovine serum and
was passaged into 6-well culture plates (Corning, Inc., Corning,
NY, USA) at 5  105 cells per well. The cells were transfected with
50 nM hsa-miR-1283 mimics, 100 nM hsa-miR-1283 inhibitor and
50 nM scrambled negative control siRNA respectively by means of
lipofectamine 2000. Thirty-six hours after transfection, cells were
harvested and the expression levels of hsa-miR-1283 and ATF1
mRNA were detected by real-time PCR analysis. The primers were
shown in supplementary information.
2.8. ROS detection
Thirty-six hours after transfected with hsa-miR-1283 mimics,
inhibitor and negative control siRNA, changed the medium with
10 lM DCFH-DA and incubated for 45 min. The ﬂuorescence was
detected by means of ﬂuorescence microplate reader with excita-
tion wavelength of 485 nm and emission wavelength of 525 nm,
respectively. The relatively expression level of ROS was calculated
as: ROS (%) = intervention group/control group  100%.
2.9. Statistical analysis
SPSS19.0 (Version 19.0; SPSS, Chicago, Illinois) was used for sta-
tistical analysis. Categorical variables were expressed as propor-
tions (%) and continuous variables as mean ± standard deviation.
All comparisons between EH group and the control group for con-
tinuous variables were performed by independent t-test, and com-
parisons among genotypic groups were analyzed with one-way
ANOVA followed by LSD test and multiple comparisons. The
chi-square test was performed to compare the genotypic/allelic
frequencies and the presence of Hardy–Weinberg equilibrium.
Genetic models were divided into additive (the genotypes TT, TC
and CC were coded as 0, 1 and 2, respectively), dominant (the
genotype TT was coded as 0, and genotypes TC and CC were coded
as 1) and recessive (the genotypes of TT and TC were coded as 0,
and genotype CC was coded as 1) models, and multivariate analysis
was done by logistic regression adjusted for covariates to calculate
odds ratios (ORs) with 95% conﬁdence intervals (95% CI) in predict-
ing the risk of EH. And the parameters signiﬁcantly differentbetween the EH and control groups were chosen as the covariates.
All reported P-values were two-tailed, and statistical signiﬁcance
was set at P < 0.05.3. Results
3.1. The function of hsa-miR-1283 was most likely modiﬁed by
rs11169571 polymorphism of ATF1 gene
By in silico analysis, the SNP rs11169571 was within the predic-
tive miRNA binding region with MAF > 0.05 in Asian population.
The miRNAs being affected by this SNP on database MirSNP were
listed in Table 1. It seemed that the SNP rs11169571 destroyed
the binding of several miRNAs with ATF1 because of the mutation
from T to C. Among the miRNAs, hsa-miR-1283 showed the great-
est changed energy from T to C and got the highest score.3.2. The rs11169571 polymorphism was associated with increased risk
for EH
We carried out a case-control study for analysis of the associa-
tion of rs11169571 with essential hypertension. The results of
genotyping identiﬁed by PCR–RFLP and validation by sequencing
were shown in Fig. 1. The clinical characteristics of the participants
were shown in Table 2. No signiﬁcant difference in age and sex
between the EH and control groups was seen because they were
matched during the sample selection. In addition to the difference
in blood pressure measurements, signiﬁcant differences in BMI, TG,
TC, FBG and smoking history were observed between the two
groups (P < 0.05), which could be risk factors of EH. The expression
levels of ATF1 in the EH and control groups were shown in Fig. 2.
People with EH had a signiﬁcantly increased ATF1 expression level
than that of the controls (P < 0.01).
The genotypic distribution of rs11169571 in both EH patients
and the controls was in Hardy–Weinberg equilibrium (P > 0.05).
Univariate analysis between rs11169571 and EH was conducted,
which showed that the three genetic models all associated with
EH (Table 3). However, in multivariate logistic regression analysis,
only recessive genetic model of rs11169571 remained signiﬁcantly
associated with EH independent of traditional environment risk
factors, as shown in Table 4, a signiﬁcantly higher prevalence of
C allelic frequency (P = 0.012, OR = 2.358, 95% CI: 1.206–4.608)
was observed in the hypertensives than that in the normotensives,
which suggested that the C allele might be a risk factor for the EH
in the Northeastern Han Chinese. No signiﬁcant difference was
found in additive and dominant genetic models (P > 0.05). We fur-
ther analyzed the clinical characteristics according to rs11169571
genotypes among EH patients who never treated with
anti-hypertensive drugs. The results were shown in supplementary
data. We failed to show any signiﬁcant association between the
polymorphism and blood pressure. However, there was a tendency
with the CC genotype to show higher blood pressure than those
Fig. 1. PCR-RLFP detection results for rs11169571 genotyping. We determined the three genotypes by Hind III digestion fragments and validated by sequencing. TT genotype
was digested into 159 and 67 bp fragments. CC genotype was not digested and only included a 226 bp fragment. TC genotype was heterozygous with one digested and the
other not digested.
Table 2
The clinical characteristics of participants in the case-control analysis.
Case (n = 378) Control
(n = 423)
t/x2 P
Age (year) 46.93 ± 9.384 45.95 ± 10.371 1.431 0.153
Sex (M/F) 242/178 232/193 0.788 0.406
SBP (mmHg) 155.17 ± 18.753 116.63 ± 11.232 36.133 0.000
DBP (mmHg) 96.09 ± 11.891 72.36 ± 8.963 32.672 0.000
HR (bpm) 79.40 ± 12.718 74.47 ± 10.045 5.957 0.000
BMI (kg/m2) 24.37 ± 2.793 23.39 ± 2.877 4.418 0.000
HDL-c (mmol/L) 1.13 ± 0.290 1.15 ± 0.260 1.162 0.245
LDL-c (mmol/L) 3.02 ± 0.873 2.85 ± 0.690 3.070 0.000
TG (mmol/L) 2.31 ± 2.069 1.68 ± 1.259 5.270 0.000
TC (mmol/L) 5.01 ± 1.006 4.69 ± 0.837 4.860 0.000
FBG (mmol/L) 5.50 ± 1.139 5.06 ± 0.734 6.482 0.000
Drinking history
(yes/no)
76/181 68/149 0.173 0.690
Smoking history
(yes/no)
92/165 58/159 4.474 0.034
Fig. 2. The expression levels between the EH and Control group. The expression of
ATF1 protein in the peripheral blood of EH patients was signiﬁcantly higher than
the control. **Indicates P < 0.05 compared with control.
Table 3
Univariate logistic regression analysis between rs11169571 and EH.
Variable OR 95% CI P
Recessive model 1.691 1.063–2.689 0.027
Additive model 1.500 1.207–1.866 0.000
Dominant model 1.662 1.248–2.215 0.001
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addition, we observed that the CC genotype tended to have a
higher LDL-c level than TT and TC genotypes (3.21 vs. 2.85 and
3.07).3.3. rs11169571 affects ATF1 protein level in EH patients
To determine the effect of rs11169571 on ATF1 expression, we
detected the expression of ATF1 in the peripheral blood of EH
patients with rs11169571 genotypes of TT, TC or CC. Using ELISA
detection, we observed a signiﬁcant increase in ATF1 protein level
in CC carriers to the TT carriers (P < 0.01) (Fig. 3). It also showed an
intermediate increase in ATF1 protein in EH patients of TC carriers,
supporting a dose-dependent increase of ATF1 with each C allele.
3.4. rs11169571 modiﬁed the binding of hsa-miR-1283 to ATF1
To test the actual effect of rs11169571 on the stabilization of
hsa-miR-1283: ATF1 30UTR hybrid complex, we cloned and
cotransfected hsa-miR-1283 and the luciferase reporter vector of
the 30UTR of ATF1 gene with either –T or –G allele of rs11169571
into 293T cells. The results showed that co-transfection of
hsa-miR-1283 signiﬁcantly inhibited the luciferase activity of the
reporter vector carrying –T allele (P < 0.05), but not the –C allele
(P = NS) (Fig. 4).
3.5. Over-expression of hsa-miR-1283 reduced the mRNA level of ATF1
in HA-VSMCs
To test whether hsa-miR-1283 expressed in HA-VSMCSs, we
detected the levels of hsa-miR-1283 after transfected with its
mimics and inhibitor into the HA-VSMCs compared with the neg-
ative control, which showed that the expression level of
hsa-miR-1283 was signiﬁcantly changed after transfected with
its speciﬁc mimics and inhibitor compared with the negative con-
trol, which showed that hsa-miR-1283 could be expressed by
HA-VSMCs (Fig. 5A). In addition, we tested the ATF1 mRNA levels
Table 4
Multivariate logistic regression analysis of determinants of EH in subjects.
Variables OR 95% CI P
BMI (kg/m2) 1.095 1.019–1.177 0.013
LDL-c (mmol/L) 0.978 0.591–1.617 0.930
TG (mmol/L) 1.120 0.937–1.339 0.214
TC (mmol/L) 1.072 0.684–1.679 0.762
FBG (mmol/L) 2.054 1.532–2.752 0.000
Smoking history 1.401 0.909–2.161 0.127
Recessive model of
rs11169571 (CC vs. TC + TT)
2.358 1.206–4.608 0.012
Fig. 3. The expression of ATF1 protein in peripheral blood of EH patients. The CC
carriers had a signiﬁcant increase in ATF1 protein level than those of TT and TC
carriers. Also an intermediate increase in ATF1 protein was seen in TC carriers.
**P < 0.01 compared with TT genotype; ##P < 0.01 compared with TC genotype.
Fig. 4. Effect of rs11169571 (T < C) of ATF1 on miR-1283 binding. Luciferase assay
for miR-1283 to ATF1 vector with either –T or –C allele. 293T cells were
cotransfected with miR-1283 or scrambled miR-controls. Forty-eight hours after
transfection, luciferase activities were measured and normalized to the luciferase
expression of empty pmiR-RB-Reporter vector, and the mean activities ± S.E. from
ﬁve independent experiments were shown. *P < 0.05 miR-1283/rs11169571-T vs.
control.
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the ATF1 mRNA level, while over-expression of miR-1283 could
reduce the ATF1 mRNA level to some extent, although the differ-
ence was not signiﬁcant, which suggested that miR-1283 might
play a role in the HA-VSMCS through targeting ATF1 (Fig. 5B).Fig. 5. The relative expression of ATF1 mRNA and ROS after intervention of miR-1283 in
regulated in HA-VSMCs after transfected with miR-1283 mimics and inhibitor, respecti
However, inhibition of miR-1283 in HA-VSMCs signiﬁcantly increased the ROS level (B)3.6. The production of ROS in HA-VSMCs was changed by hsa-miR-
1283
To test the role of hsa-miR-1283 in HA-VSMCs, we detected the
expression level of ROS after transfection with hsa-miR-1283 mim-
ics and inhibitor. The ROS level was signiﬁcantly down-regulated
after transfected with miR-1283 mimics. However, the difference
between miR-1283 inhibitor and control group was not signiﬁcant,
which suggested that miR-1283 level might be related with the
ROS production in HA-VSMCs (Fig. 5B).
4. Discussion
In the present study, we found that rs11169571 of ATF1 gene
might be associated with increased risk of essential hypertension,
and we suggested that the SNP-modiﬁed post-transcriptional gene
regulation by miRNAs might be a potentially pathogenetic mecha-
nism of EH.
In the present case-control study, we observed that the C allele
of rs11169571 was signiﬁcantly associated with increased risk of
EH. Subjects with the CC genotype were more likely to develop
hypertension than those with the TC and TT genotypes.
Consistent with this association, subjects with the CC genotype
in the present study also tended to have higher blood pressure
than those with the TC or TT genotypes, although this tendency
was not signiﬁcant.
ATF1 rs11169571 was previously reported to be associated with
the development of breast/ovarian cancer among BRCA2 mutation
carriers, yet the mechanism remained unclear [19]. Previous
reports showed that NOX1 mediated the proliferation and hyper-
trophy of VSMCs with the stimulation of angiotensin II, phorbol
ester, aldosterone, PDGF (platelet-derived growth factor) or PG
(prostaglandin)F2a [10,24,25]. On the other hand, ATF1 played an
pivotal role in the regulation of NOX1, either through PI3
kinase-ATF-1 pathway or Src-ATF-1 pathway [12,13]. In addition,
increased ROS levels—induced by NOX1—could decrease NO
bioavailability, augment vascular tone, and ﬁnally result in hyper-
tension [26]. Therefore, these data suggested that rs11169571
increased EH susceptibility, and the underlying mechanism might
be mediated by affecting ATF1 to regulate the expression of
NOX1 and ROSs.
We go further to examine ATF1 protein level in EH patients with
different rs11169571 genotypes. We found a signiﬁcant increase in
ATF1 protein levels in CC carriers relative to the TT carriers, with an
intermediate ATF1 level in TC carriers. This data supported the
translational suppression of ATF1 by miRNAs. In addition, these
ﬁndings consistently suggested that the C allele of rs11169571
altered ATF1 levels and was therefore associated with EH.
However, hypertension was known a multifactorial disease
involved in deregulation of neuro-hormonal systems, especiallyHA-VSMCs. The expression of miR-1283 was signiﬁcantly up-regulated and down-
vely (A). ATF1 mRNA level was signiﬁcantly decreased in miR-1283 mimics group.
. **P < 0.01 compared with the control group.
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genetic changes may just be secondary to blood pressure changes.
To validate the association, in vitro experiments were further
conducted.
Previous reports showed that SNPs in the 30UTR alter miRNA
regulation of the target genes [16–18]. In this study, we used the
online bioinformatic database developed by Liu et al. [20] to iden-
tify the miRNAs with function-modiﬁed by rs11169571, and found
the energy of miRNAs: ATF1 30UTR was greatly changed by
rs11169571 (T > C), which seemed the mutant C allele might
destroy the binding of ATF1 mRNA and several miRNAs. Among
the putative altered miRNAs, hsa-miR-1283 was with greatest
changed energy between T and C allele of rs11169571. Therefore,
we speculated that rs11169571 might modulate the regulation of
hsa-miR-1283 to ATF1 and lead to differences in the susceptibility
to EH.
The luciferase results showed that hsa-miR-1283 actually binds
more efﬁciently to the –T allele than the mutant –C allele of
rs11169571, which was in consistency with the in silico analysis
to suggest the functional interaction between hsa-miR-1283 and
ATF1 30UTR mRNA. Hsa-miR-1283 is located in chromosome 19
and belongs to miR-515 family. Some preliminary studies have
identiﬁed hsa-miR-1283 as a placenta-associated miRNA [27].
However, no studies can be found for hsa-miR-1283 in EH. In the
present study, we identiﬁed that hsa-miR-1283 was expressed by
HA-VSMCs as well. Moreover, inhibition of miR-1283 could
increase the expression level of ATF1 mRNA. In addition,
over-expression of miR-1283 in HA-VSMCs signiﬁcantly
up-regulated the ROS levels. Based on our results, hsa-miR-1283
might be involved in EH by targeting ATF1 to modulate the ROS
expression, which can be altered by rs11169571.
In conclusion, our results suggested that the rs11169571 (T > C)
polymorphism may be associated with increased risk for essential
hypertension. There were several limitations in our study. Firstly,
the familiarity was an important variable for an association study
between a SNP and the hypertensive pathology, which was not
taken into account in our case-control study. Secondly, we chose
hsa-miR-1283 based on the UTR free energy variation, while the
energy was not very different compared to the other 2 predicted
miRNAs. We would check whether also miR-520-5d and
miR-524d-5p behave like miR-1283 in the modulation of the
ATH1 luciferase activity and whether they are expressed by SMCs
in further study. Thirdly, the ATF1 protein levels were not tested
after transfected with miR-1283 mimics or inhibitor. Further
investigations are left to explore the underlying miRNA-mediated
mechanisms that are modiﬁed by ATF1 rs11169571 via several cell
models as well as transgenic animal models.
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